Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

TIGIT inhibitor

DRUG CLASS:

TIGIT inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	atezolizumab + RG6058 Sensitive: B - Late Trials atezolizumab + RG6058 Sensitive : B	atezolizumab + RG6058 Sensitive: B - Late Trials atezolizumab + RG6058 Sensitive : B
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	atezolizumab + RG6058 Sensitive: C2 – Inclusion Criteria atezolizumab + RG6058 Sensitive : C2	atezolizumab + RG6058 Sensitive: C2 – Inclusion Criteria atezolizumab + RG6058 Sensitive : C2
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	zimberelimab + AB154 + AB928 Sensitive: C2 – Inclusion Criteria zimberelimab + AB154 + AB928 Sensitive : C2	zimberelimab + AB154 + AB928 Sensitive: C2 – Inclusion Criteria zimberelimab + AB154 + AB928 Sensitive : C2
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	zimberelimab + AB154 Sensitive: C2 – Inclusion Criteria zimberelimab + AB154 Sensitive : C2	zimberelimab + AB154 Sensitive: C2 – Inclusion Criteria zimberelimab + AB154 Sensitive : C2
PD-L1 expression	Esophageal Cancer	PD-L1 expression	Esophageal Cancer	atezolizumab + RG6058 Sensitive: C2 – Inclusion Criteria atezolizumab + RG6058 Sensitive : C2	atezolizumab + RG6058 Sensitive: C2 – Inclusion Criteria atezolizumab + RG6058 Sensitive : C2
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	tislelizumab-jsgr + BGB-A1217 Sensitive: C2 – Inclusion Criteria tislelizumab-jsgr + BGB-A1217 Sensitive : C2	tislelizumab-jsgr + BGB-A1217 Sensitive: C2 – Inclusion Criteria tislelizumab-jsgr + BGB-A1217 Sensitive : C2
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	tislelizumab-jsgr + BGB-A1217 Sensitive: C2 – Inclusion Criteria tislelizumab-jsgr + BGB-A1217 Sensitive : C2	tislelizumab-jsgr + BGB-A1217 Sensitive: C2 – Inclusion Criteria tislelizumab-jsgr + BGB-A1217 Sensitive : C2
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	AZD2936 Sensitive: C2 – Inclusion Criteria AZD2936 Sensitive : C2	AZD2936 Sensitive: C2 – Inclusion Criteria AZD2936 Sensitive : C2
PD-L1 expression	Esophageal Adenocarcinoma	PD-L1 expression	Esophageal Adenocarcinoma	tislelizumab-jsgr + BGB-A1217 Sensitive: C2 – Inclusion Criteria tislelizumab-jsgr + BGB-A1217 Sensitive : C2	tislelizumab-jsgr + BGB-A1217 Sensitive: C2 – Inclusion Criteria tislelizumab-jsgr + BGB-A1217 Sensitive : C2
PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	pembrolizumab + MK-7684 Sensitive: C3 – Early Trials pembrolizumab + MK-7684 Sensitive : C3	pembrolizumab + MK-7684 Sensitive: C3 – Early Trials pembrolizumab + MK-7684 Sensitive : C3
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	sintilimab + IBI-939 Sensitive: C3 – Early Trials sintilimab + IBI-939 Sensitive : C3	sintilimab + IBI-939 Sensitive: C3 – Early Trials sintilimab + IBI-939 Sensitive : C3
TP53 mutation	Non Small Cell Lung Cancer	TP53 mutation	Non Small Cell Lung Cancer	HB0030 Sensitive: C3 – Early Trials HB0030 Sensitive : C3	HB0030 Sensitive: C3 – Early Trials HB0030 Sensitive : C3
TIGIT expression	Esophageal Adenocarcinoma	TIGIT expression	Esophageal Adenocarcinoma	tislelizumab-jsgr + BGB-A1217 Sensitive: C3 – Early Trials tislelizumab-jsgr + BGB-A1217 Sensitive : C3	tislelizumab-jsgr + BGB-A1217 Sensitive: C3 – Early Trials tislelizumab-jsgr + BGB-A1217 Sensitive : C3
TIGIT expression	Esophageal Squamous Cell Carcinoma	TIGIT expression	Esophageal Squamous Cell Carcinoma	tislelizumab-jsgr + BGB-A1217 Sensitive: C3 – Early Trials tislelizumab-jsgr + BGB-A1217 Sensitive : C3	tislelizumab-jsgr + BGB-A1217 Sensitive: C3 – Early Trials tislelizumab-jsgr + BGB-A1217 Sensitive : C3
PD-L1 overexpression	Esophageal Adenocarcinoma	PD-L1 overexpression	Esophageal Adenocarcinoma	zimberelimab + AB154 Sensitive: C3 – Early Trials zimberelimab + AB154 Sensitive : C3	zimberelimab + AB154 Sensitive: C3 – Early Trials zimberelimab + AB154 Sensitive : C3
PD-L1 overexpression	Gastric Cancer	PD-L1 overexpression	Gastric Cancer	zimberelimab + AB154 Sensitive: C3 – Early Trials zimberelimab + AB154 Sensitive : C3	zimberelimab + AB154 Sensitive: C3 – Early Trials zimberelimab + AB154 Sensitive : C3
PD-L1 overexpression	Gastroesophageal Junction Adenocarcinoma	PD-L1 overexpression	Gastroesophageal Junction Adenocarcinoma	zimberelimab + AB154 Sensitive: C3 – Early Trials zimberelimab + AB154 Sensitive : C3	zimberelimab + AB154 Sensitive: C3 – Early Trials zimberelimab + AB154 Sensitive : C3
BRAF mutation	Melanoma	BRAF mutation	Melanoma	EOS-448 Sensitive: C4 – Case Studies EOS-448 Sensitive : C4	EOS-448 Sensitive: C4 – Case Studies EOS-448 Sensitive : C4